Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, Follicular

Explore clinical trials studying Lymphoma, Follicular. Study availability and eligibility vary by location and protocol.

53 public trials 7 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, Follicular trial results

Active, not recruiting

Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells

NCT04911478

Conditions
Diffuse Large B Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +14 more
Locations
  • Blood and Marrow Transplant Program Palo Alto, California, United States
  • Norton Cancer Institute Louisville, Kentucky, United States
  • Baylor Scott & White Research Institute Dallas, Texas, United States
  • MD Anderson Caner Center Houston, Texas, United States
View Trial Details
Active, not recruiting

A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan

NCT05228158

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
Locations
  • Eisai Trial Site 131 Komaki-shi, Aichi-ken, Japan
  • Eisai Trial Site 199 Konan-shi, Aichi-ken, Japan
  • Eisai Trial Site 21 Nagakute-shi, Aichi-ken, Japan
  • Eisai Trial Site 106 Nagoya, Aichi-ken, Japan
View all 135 locations
View Trial Details
Active, not recruiting

A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma

NCT03934567

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +11 more
Locations
  • Cancer Hospital Chinese Academy of Medical Sciences Beijing, China
  • China-Japan Friendship Hospital Beijing, China
  • Peking University Third Hospital Beijing, China
  • Jilin Cancer Hospital Changchun, China
View all 26 locations
View Trial Details
Completed

Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Relapsed Follicular Lymphoma

NCT01208896

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • University Hospital Angers Angers, France
  • Service Hématologie, Hôpital Minjoz Besançon, France
  • Service Hématologie, Hôpital Augustin Morvan Brest, France
  • University Hospital, Caen Caen, France
View all 26 locations
View Trial Details
Completed

A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial)

NCT02278796

Conditions
Dendritic Cell Sarcoma, Interdigitating, Hemic and Lymphatic Diseases, Histiocytic Disorders, Malignant, +13 more
Locations
  • Krankenhaus der Elisabethinen Linz Linz, Austria
  • Hanusch Krankenhaus Wien Vienna, Austria
  • Department for Medical Oncology University Hospital/Inselspital Bern, Switzerland
  • Universitätsspital Zürich Zurich, Switzerland
View Trial Details
Completed

A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5q or Refractory/Relapsed Mantle Cell Lymphoma in Korea

NCT04036448

Conditions
Bone Marrow Diseases, Disease Attributes, Hematologic Diseases, +15 more
Locations
  • Local Institution - S02 Seoul, Seoul Teugbyeolsi, South Korea
  • Hallym University Medical Center Anyang, South Korea
  • Keimyung University Dongsan Hospital Daegu, South Korea
  • Kyungpook National University Hospital Daegu, South Korea
View all 26 locations
View Trial Details
Completed

A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies

NCT03310619

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Local Institution - 011 Duarte, California, United States
  • Local Institution - 022 Atlanta, Georgia, United States
  • Local Institution - 014 Chicago, Illinois, United States
  • Local Institution - 012 Boston, Massachusetts, United States
View Trial Details

Related conditions